Unlikely to cause harm — often a labeling or packaging issue.
Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.
| Brand name | NILOTINIB |
| Generic name | NILOTINIB |
| Active ingredient(s) | NILOTINIB |
| Distributed by / for | Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059, Outer carton: 112 capsules (4 individual packs containing 28 capsules each) |
| NDC | 69097-032-74 |
| Full product label | Nilotinib Capsules, 200 mg per capsule, packaged in cartons, Rx only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059, Outer carton: 112 capsules (4 individual packs containing 28 capsules each), NDC 69097-032-74; Inner carton: 28 capsules (4 blisters of 7 capsules), NDC 69097-032-56; Foil blister: NDC 69097-032-17 |
| Recalling firm | Cipla USA, Inc. |
| Distribution | U.S.A. Nationwide |
| Quantity | 164 cartons |
| Recall initiated | 2026-02-18 |
| Report date | 2026-03-11 |
| Recall completed | — |
| Recall number | D-0382-2026 |
| Classification | Class III |
| FDA status | Ongoing |
| Origin on file | Warren NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗